May 17, 2020

BlackBerry is set to build a new secure, global healthcare ecosystem  

Digital health
medical devices
medical devices
Digital health
Catherine Sturman
3 min
BlackBerry - Flickr (Enrique Dans)
BlackBerry Limitedhas announced its plans to transform the global delivery of patient care enabled by the Enterprise of Things (EoT) with the support of...

BlackBerry Limited has announced its plans to transform the global delivery of patient care enabled by the Enterprise of Things (EoT) with the support of its partners. By harnessing the company’s renowned carrier-grade network operation centre (NOC) to power a blockchain digital ledger, provided by ONEBIO, a secure global ecosystem for the storing and sharing of medical data, can be anonymised, will be created.

“We are applying our expertise in security, data privacy, and communication work in regulated industries such as automotive, financial services, and government to tackle one of the biggest challenges in the healthcare industry: leveraging healthcare endpoints to improve patient outcomes while ensuring security and data privacy,” said John Chen, Executive Chairman and CEO of BlackBerry.

By offering its new secure blockchain solution to the Global Commission, an organisation focused on ending the diagnostic odyssey for children with a rare disease, one of the company’s technology pilots will look at how Blackberry’s new solution could provide real-time, actionable analysis as the Commission seeks to use technology to shorten the time to diagnosis.   

Compliant with IEC 62304 safety-certification standards, BlackBerry’s new QNX OS for Medical 2.0 is a real-time operating system for the development of robotic surgical instruments, patient monitoring systems, infusion pumps, blood analysis systems, and other safety-critical products that must pass stringent regulatory approval.

With QNX OS for Medical 2.0, medical device manufacturers have the assurance of using trusted software field-proven in thousands of life-critical environments, including in FDA Class III medical devices.

See also

Additionally, The Mackenzie Innovation Institute (Mi2) is exploring security and connectivity between the BlackBerry Spark platform and its ‘smart’ healthcare technology vision. Mi2 helps drive innovation in healthcare through research, education and training while enhancing healthcare practices, treatments, service delivery models and more.

“By developing a deeper understanding and exploring how our ‘smart’ systems operate with BlackBerry Spark, we aim to uncover new ways to connect, protect and intuitively manage smart technologies in a hospital and positively impact high-quality patient care,” says Richard Tam, Chief Financial Officer of Mi2. “Together, we will focus on comprehensive security, patient privacy and intelligent connectivity, all the while achieving the vision of the Internet of Healthcare Things (IoHT).”

Mi² is a bridge between industry and healthcare for the implementation and evaluation of innovative and disruptive technologies, process redesign, and practice changes in real-time healthcare environments in order to create sustainable value-added improvements in patient experience, quality and outcomes.

Not content with this, BlackBerry has also collaborated with the Melanoma Institute Australia (MIA). Pioneering the prevention and cure of melanoma through world-class research, treatment and education programmes, the company has selected BlackBerry to enable researchers to securely share critical research data and patient records in a heavily regulated environment. 

Approved contributors in the network, such as scientists and doctors at different hospitals, can use BlackBerry Workspaces to save and share data from medical histories and clinical trials to assess the effectiveness of treatments and interventions. The easy-to-use, encrypted collaboration solution will enable researchers to share timely clinical data, reduce the risk of data leakage, and accelerate research efforts.

Ernie White, Chief Information Officer of Melanoma Institute of Australia commented, “Our priority is to advance the treatment of melanoma, so any new technology must support the clinical journey for our clinicians, not interrupt it. As we continue to expand our research network, Melanoma Institute Australia is accelerating how our researchers can freely collaborate in a very regulated environment, while maintaining data integrity. BlackBerry Workspaces strikes that balance between security and ease-of-use, while helping to meet data compliance and our own digital transformation goals.” 

 

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

AI
medication
personalisedmedicine
chronicdisease
3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article